VIENNA, Va., Sept. 22 /PRNewswire-FirstCall/ -- CEL-SCI Corporation
(Amex: CVM) conducted an interview with SmallCap Network that was published
Friday morning, September 22, 2006. The interview with the CEO of CEL-SCI,
Geert Kersten, is in a question and answer format that addresses the
current operations and future prospects of the Company. Interested parties
may go to http://smallcapnetwork.net/archive/listserv/20060922-1.html to
read the interview.
The SmallCap Network is a leading financial publisher dedicated to
providing investors with information on equities in the small cap sector.
They publish a weekly financial newsletter via email. The newsletter
focuses on stocks in the small cap sector that have the potential to
appreciate significantly in the future. With over 900,000 members, the
SmallCap Network is one of the fastest-growing financial newsletters on the
Internet.
CEL-SCI Corporation is developing new immune system based treatments
for cancer and infectious diseases. The Company has operations in Vienna,
Virginia and Baltimore, Maryland. The Company's lead product Multikine(R)
is cleared to enter global Phase III clinical trials in advanced primary
head and neck cancer patients. CEL-SCI's other products, which are
currently in the pre-clinical stage and are funded with U.S. government
support, have shown protection against a number of diseases in animal tests
and are being tested against diseases associated with bio-defense and avian
flu.
SOURCE CEL-SCI Corporation
 back to top
Related links:
http://www.cel-sci.com
CONTACT:
Gavin de Windt of CEL-SCI Corporation,
+1-703-506-9460
|
